实体瘤治疗疗效评价标准——RECIST

RECIST-New guidelines to evaluate the response to treatment in solid tumors

实体瘤治疗疗效评价标准的发展已有近40年的历史。RECIST已成为目前国际肿瘤界采用的新标准。与WHO标准相比,RECIST更强调测量的易重复性和易追踪。RECIST可以简要概括如下:以肿瘤最长径(需≥20mm)为测量基线。治疗后,肿瘤最长径缩小≥30%为部分缓解,增大≥20%则为疾病进展。建议国内肿瘤界应尽快转向以RECIST对肿瘤进行测量和评价的体系。

The response evaluation criteria for the treatment of solid tumors has been developed for nearly 40 years. RECIST(Response Evaluation Criteria In Solid Tumors) was adopted as the new criteria recently. Compared to WHO criteria, RECIST underscore reevaluation and follow-up. RECIST can be summarized as follows: baseline measure the longest diameter(LD) of target lesions(≥20 mm). After treatment, sums of LD of all target lesions decrease by ≥30% defined as PR, sums of LD of all target lesions increase by ≥20% defined as PD. The authors suggest timely shift from WHO criteria to RECIST.